- Home
- TEL vs TAK Comparison
TEL vs TAK Comparison
Compare TEL & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TEL | TAK |
|---|---|---|
| Founded | 1941 | 1781 |
| Country | Ireland | Japan |
| Employees | N/A | 47455 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.9B | 52.4B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | TEL | TAK |
|---|---|---|
| Price | $210.40 | $15.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $257.27 | N/A |
| AVG Volume (30 Days) | 2.3M | ★ 3.0M |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | 1.38% | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.42 | N/A |
| Revenue | ★ $17,262,000,000.00 | N/A |
| Revenue This Year | $14.07 | $0.16 |
| Revenue Next Year | $7.74 | $1.22 |
| P/E Ratio | ★ $38.31 | $41.25 |
| Revenue Growth | ★ 8.94 | N/A |
| 52 Week Low | $162.17 | $12.99 |
| 52 Week High | $252.56 | $18.90 |
Technical Indicators
Market Signals| Indicator | TEL | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 46.93 |
| Support Level | $207.88 | $15.63 |
| Resistance Level | $218.43 | $16.48 |
| Average True Range (ATR) | 7.93 | 0.21 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 43.19 | 77.27 |
Price Performance
Historical ComparisonAbout TEL TE Connectivity Ltd. New Switzerland Registered Shares
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.